Published in Medical Letter on the CDC and FDA, January 25th, 2004
The Office of Generic Drugs, FDA, has determined the Ranbaxy formulations to be bioequivalent and, has the same therapeutic effect as the reference listed drug Ceclor Liquid, 125 mg, 187 mg, 250 mg and 375 mg, respectively, of Eli Lilly and Company.
RPI will be responsible for marketing this product under the brand name Raniclor in this newly formulated dosage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA